Simvastatin activates the spindle assembly checkpoint and causes abnormal cell division by modifying small GTPases
In this study, we determined its effect on cell division. Cell cycle synchronization experiments revealed a delay in mitotic progression in simvastatin-treated cells at concentrations lower than the IC50. Time-lapse imaging analysis indicated that the duration of mitosis, especially from mitotic entry to anaphase onset, was prolonged. In addition, simvastatin increased the number of cells exhibiting misoriented anaphase/telophase and bleb formation. Inhibition of the spindle assembly checkpoint (SAC) kinase Mps1 canceled the mitotic delay. Additionally, the number of cells exhibiting kinetochore localization of BubR1, an e...
Source: Cellular Signalling - April 11, 2024 Category: Cytology Authors: Junna Tanaka Hiroki Kuwajima Ryuzaburo Yuki Yuji Nakayama Source Type: research
Simvastatin activates the spindle assembly checkpoint and causes abnormal cell division by modifying small GTPases
In this study, we determined its effect on cell division. Cell cycle synchronization experiments revealed a delay in mitotic progression in simvastatin-treated cells at concentrations lower than the IC50. Time-lapse imaging analysis indicated that the duration of mitosis, especially from mitotic entry to anaphase onset, was prolonged. In addition, simvastatin increased the number of cells exhibiting misoriented anaphase/telophase and bleb formation. Inhibition of the spindle assembly checkpoint (SAC) kinase Mps1 canceled the mitotic delay. Additionally, the number of cells exhibiting kinetochore localization of BubR1, an e...
Source: Cellular Signalling - April 11, 2024 Category: Cytology Authors: Junna Tanaka Hiroki Kuwajima Ryuzaburo Yuki Yuji Nakayama Source Type: research
Simvastatin activates the spindle assembly checkpoint and causes abnormal cell division by modifying small GTPases
In this study, we determined its effect on cell division. Cell cycle synchronization experiments revealed a delay in mitotic progression in simvastatin-treated cells at concentrations lower than the IC50. Time-lapse imaging analysis indicated that the duration of mitosis, especially from mitotic entry to anaphase onset, was prolonged. In addition, simvastatin increased the number of cells exhibiting misoriented anaphase/telophase and bleb formation. Inhibition of the spindle assembly checkpoint (SAC) kinase Mps1 canceled the mitotic delay. Additionally, the number of cells exhibiting kinetochore localization of BubR1, an e...
Source: Cellular Signalling - April 11, 2024 Category: Cytology Authors: Junna Tanaka Hiroki Kuwajima Ryuzaburo Yuki Yuji Nakayama Source Type: research
Simvastatin activates the spindle assembly checkpoint and causes abnormal cell division by modifying small GTPases
In this study, we determined its effect on cell division. Cell cycle synchronization experiments revealed a delay in mitotic progression in simvastatin-treated cells at concentrations lower than the IC50. Time-lapse imaging analysis indicated that the duration of mitosis, especially from mitotic entry to anaphase onset, was prolonged. In addition, simvastatin increased the number of cells exhibiting misoriented anaphase/telophase and bleb formation. Inhibition of the spindle assembly checkpoint (SAC) kinase Mps1 canceled the mitotic delay. Additionally, the number of cells exhibiting kinetochore localization of BubR1, an e...
Source: Cellular Signalling - April 11, 2024 Category: Cytology Authors: Junna Tanaka Hiroki Kuwajima Ryuzaburo Yuki Yuji Nakayama Source Type: research
Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase
Biochem Biophys Res Commun. 2024 Mar 28;710:149841. doi: 10.1016/j.bbrc.2024.149841. Online ahead of print.ABSTRACTProstate cancer is the most prevalent malignancy in men. While diagnostic and therapeutic interventions have substantially improved in recent years, disease relapse, treatment resistance, and metastasis remain significant contributors to prostate cancer-related mortality. Therefore, novel therapeutic approaches are needed. Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway which plays an essential role in cholesterol homeostasis. N...
Source: Biochemical and Biophysical Research communications - April 8, 2024 Category: Biochemistry Authors: Andy G öbel Sophie P ählig Anja Motz Dorit Breining Sofia Traikov Lorenz C Hofbauer Tilman D Rachner Source Type: research
Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase
Biochem Biophys Res Commun. 2024 Mar 28;710:149841. doi: 10.1016/j.bbrc.2024.149841. Online ahead of print.ABSTRACTProstate cancer is the most prevalent malignancy in men. While diagnostic and therapeutic interventions have substantially improved in recent years, disease relapse, treatment resistance, and metastasis remain significant contributors to prostate cancer-related mortality. Therefore, novel therapeutic approaches are needed. Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway which plays an essential role in cholesterol homeostasis. N...
Source: Cell Research - April 8, 2024 Category: Cytology Authors: Andy G öbel Sophie P ählig Anja Motz Dorit Breining Sofia Traikov Lorenz C Hofbauer Tilman D Rachner Source Type: research
Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase
Biochem Biophys Res Commun. 2024 Mar 28;710:149841. doi: 10.1016/j.bbrc.2024.149841. Online ahead of print.ABSTRACTProstate cancer is the most prevalent malignancy in men. While diagnostic and therapeutic interventions have substantially improved in recent years, disease relapse, treatment resistance, and metastasis remain significant contributors to prostate cancer-related mortality. Therefore, novel therapeutic approaches are needed. Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway which plays an essential role in cholesterol homeostasis. N...
Source: Biochemical and Biophysical Research communications - April 8, 2024 Category: Biochemistry Authors: Andy G öbel Sophie P ählig Anja Motz Dorit Breining Sofia Traikov Lorenz C Hofbauer Tilman D Rachner Source Type: research
Idebenone ameliorates statin-induced myotoxicity in atherosclerotic ApoE-/- mice by reducing oxidative stress and improving mitochondrial function
Biochim Biophys Acta Mol Basis Dis. 2024 Apr 4:167157. doi: 10.1016/j.bbadis.2024.167157. Online ahead of print.ABSTRACTStatins are the first line of choice for the treatment for atherosclerosis, but their use can cause myotoxicity, a common side effect that may require dosage reduction or discontinuation. The exact mechanism of statin-induced myotoxicity is unknown. Previous research has demonstrated that the combination of idebenone and statin yielded superior anti-atherosclerotic outcomes. Here, we investigated the mechanism of statin-induced myotoxicity in atherosclerotic ApoE-/- mice and whether idebenone could counte...
Source: Biochimica et Biophysica Acta - April 6, 2024 Category: Biochemistry Authors: Wenfei Yu Wenjing Wu Dandan Zhao Rui ZhangMD Kai Shao Haoyang Liu Chuanzhu Yan Pengfei Lin Source Type: research
Idebenone ameliorates statin-induced myotoxicity in atherosclerotic ApoE-/- mice by reducing oxidative stress and improving mitochondrial function
Biochim Biophys Acta Mol Basis Dis. 2024 Apr 4:167157. doi: 10.1016/j.bbadis.2024.167157. Online ahead of print.ABSTRACTStatins are the first line of choice for the treatment for atherosclerosis, but their use can cause myotoxicity, a common side effect that may require dosage reduction or discontinuation. The exact mechanism of statin-induced myotoxicity is unknown. Previous research has demonstrated that the combination of idebenone and statin yielded superior anti-atherosclerotic outcomes. Here, we investigated the mechanism of statin-induced myotoxicity in atherosclerotic ApoE-/- mice and whether idebenone could counte...
Source: Atherosclerosis - April 6, 2024 Category: Cardiology Authors: Wenfei Yu Wenjing Wu Dandan Zhao Rui ZhangMD Kai Shao Haoyang Liu Chuanzhu Yan Pengfei Lin Source Type: research
Idebenone ameliorates statin-induced myotoxicity in atherosclerotic ApoE-/- mice by reducing oxidative stress and improving mitochondrial function
Biochim Biophys Acta Mol Basis Dis. 2024 Apr 4:167157. doi: 10.1016/j.bbadis.2024.167157. Online ahead of print.ABSTRACTStatins are the first line of choice for the treatment for atherosclerosis, but their use can cause myotoxicity, a common side effect that may require dosage reduction or discontinuation. The exact mechanism of statin-induced myotoxicity is unknown. Previous research has demonstrated that the combination of idebenone and statin yielded superior anti-atherosclerotic outcomes. Here, we investigated the mechanism of statin-induced myotoxicity in atherosclerotic ApoE-/- mice and whether idebenone could counte...
Source: Biochimica et Biophysica Acta - April 6, 2024 Category: Biochemistry Authors: Wenfei Yu Wenjing Wu Dandan Zhao Rui ZhangMD Kai Shao Haoyang Liu Chuanzhu Yan Pengfei Lin Source Type: research
Effect of Statin Treatment in Patients with Aneurysmal Subarachnoid Hemorrhage: A Network Meta-Analysis
ConclusionsSimvastatin 80 mg might be the most effective intervention in reducing DCI. Additionally, short-term therapy might provide more benefits. Further research with longer follow-up is warranted to validate the current findings in patients with aSAH who are at high risk of DCI. (Source: Neurocritical Care)
Source: Neurocritical Care - April 2, 2024 Category: Neurology Source Type: research
The effects of popular diets on bone health in the past decade: a narrative review
Bone health encompasses not only bone mineral density but also bone architecture and mechanical properties that can impact bone strength. While specific dietary interventions have been proposed to treat various diseases such as obesity and diabetes, their effects on bone health remain unclear. The aim of this review is to examine literature published in the past decade, summarize the effects of currently popular diets on bone health, elucidate underlying mechanisms, and provide solutions to neutralize the side effects. The diets discussed in this review include a ketogenic diet (KD), a Mediterranean diet (MD), caloric rest...
Source: Frontiers in Endocrinology - March 26, 2024 Category: Endocrinology Source Type: research
Anti-inflammatory potential of simvastatin and amfenac in ARPE-19 cells; insights in preventing re-detachment and proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery
ConclusionOur present study supports the anti-inflammatory capacity of simvastatin as pre-treatment against inflammation in human RPE cells, and the addition of amfenac complements the effect. The early modulation of local conditions in the retina can prevent inflammation induced PVR formation and subsequent retinal re-detachment. (Source: International Ophthalmology)
Source: International Ophthalmology - March 26, 2024 Category: Opthalmology Source Type: research
Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor
CONCLUSION: This cohort comprised a large proportion of patients classified as high or very high risk for ASCVD. Despite this, the use of LLT was inadequate, and <20% of patients were at target LDL-C levels. These data suggest a greater need for awareness of initiating LLT to achieve recommended target LDL-C levels in patients with CKD.PMID:38525632 | DOI:10.7196/SAMJ.2023.v113i11.1089 (Source: South African Medical Journal)
Source: South African Medical Journal - March 25, 2024 Category: African Health Authors: M R Essop F Seedat F J Raal Source Type: research
Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor
CONCLUSION: This cohort comprised a large proportion of patients classified as high or very high risk for ASCVD. Despite this, the use of LLT was inadequate, and <20% of patients were at target LDL-C levels. These data suggest a greater need for awareness of initiating LLT to achieve recommended target LDL-C levels in patients with CKD.PMID:38525632 | DOI:10.7196/SAMJ.2023.v113i11.1089 (Source: Atherosclerosis)
Source: Atherosclerosis - March 25, 2024 Category: Cardiology Authors: M R Essop F Seedat F J Raal Source Type: research
